MTOR and neuroblastoma: We and others have shown that targeting the PI3K/mTOR pathway could be a viable treatment for aggressive neuroblastoma (Chesler et al, 2006; Johnsen et al, 2008; Segerström et al, 2011; Chanthery et al, 2012; Mohlin et al, 2013, 2015; Cage et al, 2015; Stewart et al, 2015; Vaughan et al, 2016).